Credit squeeze begins to have an impact on VC

The Star-Ledger offers a new perspective on the investment scene in biotechnology. Analysts tell the newspaper that the credit crunch has put a squeeze on private equity groups who can no longer use cheap debt to buy into developers and then flip them. As a result, VCs are accepting smaller returns on smaller deals. With Big Pharma on the hunt for acquisitions, venture groups are less likely to relinquish shares before a big buyout. And buyouts have replaced IPOs as a key funding stage for biotechs.

- read the report from the Star-Ledger

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.